Improving therapeutic potential in breast cancer via histone deacetylase inhibitor loaded nanofibrils

Drug Dev Res. 2024 Apr;85(2):e22172. doi: 10.1002/ddr.22172.


Epigenetic modifications play a significant role in cancer progression, making them potential targets for therapy. Histone deacetylase inhibitors have shown promise in inhibiting cancer cell growth, including in breast cancer (BC). In this research, we examined the potential of using suberoyl anilide hydroxamic acid (SAHA)-loaded β-lg nanofibrils as a drug delivery system for triple-negative BC cell lines. We assessed their impact on cell cycle progression, apoptosis, levels of reactive oxygen species, and mitochondrial membrane potential in cancer cells. The combination of SAHA and β-lg nanofibrils demonstrated enhanced efficacy in inhibiting cell growth, inducing cell cycle arrest, and promoting apoptosis (43.78%) compared to SAHA alone (40.09%). Moreover, it effectively targeted cancer cells without promoting drug resistance while using a low concentration of the nanofibrils. These findings underscore the promising potential of nanofibril-based drug delivery systems for BC treatment.

Keywords: SAHA; apoptosis; breast cancer; histone deacetylase inhibitors; nanofibrils; β-lactoglobulin.

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Apoptosis
  • Breast Neoplasms* / drug therapy
  • Breast Neoplasms* / metabolism
  • Cell Cycle
  • Cell Line, Tumor
  • Cell Proliferation
  • Female
  • Histone Deacetylase Inhibitors / pharmacology
  • Humans
  • Hydroxamic Acids / pharmacology
  • Vorinostat / pharmacology
  • Vorinostat / therapeutic use


  • Histone Deacetylase Inhibitors
  • Hydroxamic Acids
  • Vorinostat
  • Antineoplastic Agents